Review Article
Human Polyomavirus Reactivation: Disease Pathogenesis and Treatment Approaches
Table 1
The human polyomaviruses, associated disease and immunocompromised risk groups.
| | Human polyomavirus | Adult seroprevalence | Clinical disease | Patient’s risk groups |
| | JCV | 50%–80% | Progressive multifocal leukoencephalopathy | HIV-infected, immunomodulatory therapies | | BKV | ≥90% | BKV nephropathy, haemorrhagic cystitis, ureteral stenosis | Solid organ and HSCT transplant recipients | | MCPyV | 60%–80% | Merkel cell carcinoma | >50 years of age,
immune suppression | | WUPyV | ≥69% | No strong association | Not defined | | KIPyV | ≥55% | No strong association | Not defined | | HPyV6 | ≥83% | No strong association | Not defined | | HPyV7 | ≥64% | No strong association | Not defined | | TSV | 70%–80% | Trichodysplasia spinulosa | Transplant recipients,
immune suppression | | HPyV9 | 34%–70% | No strong association | Not defined | | MWPyV | Not defined | No strong association | Not defined |
|
|
